Over the past several years, the industry has paid about $15 billion in penalties to the US government for cases involving off-label marketing and, more recently, the US Foreign Corrupt Practices Act (FCPA).
The problem with a media-megaphoned report about a drug’s potential side effect is that it too easily balloons into a fear-driven avoidance of a life-saving group of drugs.